On September 19, Gelonhui announced that in order to better leverage the effectiveness of the raised funds and improve the efficiency of fund utilization, the company plans to conclude the "Annual Production of 0.2 Billion Human-Dose In Vitro Diagnostic Reagents Production Center and R&D Center Construction Project" of the raised investment projects and permanently supplement the remaining raised funds of 38.9807 million yuan (including interest income and financial management income after deducting handling fees, the actual amount shall be subject to the balance of the special account on the day of fund transfer) as working capital for daily production and operation activities. After the transfer of the remaining raised funds, the company will handle the account closure procedures and cancel the relevant raised funds accounts according to the situation, and at the same time, the raised funds special account supervision agreement signed by the company with the sponsor institution and the opening bank will also be terminated.